| Target Audience |
| This activity has been designed to meet the educational needs of healthcare practitioners involved in the care of patients with HBV. |
| |
| Statement of Need/Program
Overview |
| The goal of this program is to provide important clinical data on the management of HBV. |
| |
| Educational Objectives |
| Upon completion of this activity, participants should be better able to: |
|
• |
Analyze new data reported at the 2011 Annual Meeting of the European Association for the Study of the Liver (EASL) on the treatment of hepatitis B and how they might modify current treatment algorithms |
| • |
Identify baseline viral biomarker characteristics that are associated with HBeAg seroconversion in HBeAg (+) patients when treated with tenofovir |
| • |
Assess the relative importance of seroclearance of HBV DNA, HBeAg, and HBsAg following treatment in predicting reduced risk for HCC |
|
| |
| Physician Accreditation
Statement |
| This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. |
| |
| Credit Designation |
| Purdue University College of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| |
| Faculty Disclosure Statement |
| All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Dr. Tran receives grants and is a consultant for Gilead, BMS, Idenix, and Schering Pharmaceuticals. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. The Focus Medical Communications staff and Purdue University School of Pharmacy staff have no relationships to disclose. |
| |
